Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Journal article
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
Teplizumab approval for type 1 diabetes in the USA.
Journal article
Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.
Journal article
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842
Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.
Journal article
Butterly E. et al, (2022), BMJ Open, 12
Endpoints and estimands: understanding trials of weight-loss drugs.
Journal article
Adler AI., (2022), Nat Med, 28, 2005 - 2006
How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?
Journal article
Cowie MR. et al, (2022), International journal of cardiology, 365, 61 - 68
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Journal article
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654
Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: A cross-sectional study.
Journal article
Bidulka P. et al, (2022), Diabetes, obesity & metabolism
NICE guidelines on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
Journal article
Adler AI. et al, (2022), Lancet Respir Med
Insulin resistance and incident heart failure: a meta-analysis.
Journal article
Erqou S. et al, (2022), European journal of heart failure
Glucocorticoid-induced hyperglycaemia and diabetes: Call for action.
Journal article
Golubic R. et al, (2022), Diabet Med
Nintedanib for treating progressive fibrosing interstitial lung diseases.
Journal article
Adler AI. et al, (2021), Lancet Respir Med
Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study.
Journal article
Bidulka P. et al, (2021), BMJ Open, 11
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Journal article
Blood Pressure Lowering Treatment Trialists' Collaboration None., (2021), Lancet, 398, 1053 - 1064
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
Journal article
Rahimi K. et al, (2021), The Lancet, 398, 1053 - 1064
Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89.
Journal article
Wamil M. et al, (2021), Diabetes Care, 44, 1877 - 1884
Accurate accounting of caplacizumab cost effectiveness – Authors' reply
Journal article
Hughes M. et al, (2021), The Lancet Haematology, 8
Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials.
Journal article
Adler AI. and Latimer NR., (2021), JAMA, 325, 2110 - 2111
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Journal article
Blood Pressure Lowering Treatment Trialists' Collaboration None., (2021), Lancet, 397, 1625 - 1636
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Journal article
Copland E. et al, (2021), Lancet Oncol, 22, 558 - 570